FABP5 and hepatocellular carcinoma: Immunohistochemistry revealed a pronounced increase in PD‐L1 expression following treatment with the targeted FABP5 co‐delivery system, suggesting that the combination of double‐loaded nanoparticles with RFA could enhance the efficacy of anti‐PD‐L1 immunotherapy in HCC (Figure 9B).